header
Local cover image
Local cover image
Image from OpenLibrary

The role of endocrine versus paracrine fibroblast growth factor and nuclear factor of activated Tcell (NFAT) signaling in cardiac remodeling and development of uremic cardiomyopathy / Nermeen Sherif Mahfouz Hafez ; Supervised Hania Ibrahim Ammar , Heba Samy Ibrahim , Asmaa Mohammed ShamsEldeen

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Nermeen Sherif Mahfouz Hafez , 2020Description: 160 P . : charts , facsmilies ; 25cmOther title:
  • دور عوامل نمو الخلايا الليفية (الهرمونية والغير هرمونية) فى اعادة تشكيل القلب وتطور اعتلال عضلة القلب الناتج عن مرضى الكلى المزمن - اعتلال القلب اليوريمى [Added title page title]
Subject(s): Online resources: Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Physiology Summary: Background, left ventricular hypertrophy (LVH) is one of the major cardiovascular complication of Chronic kidney disease (CKD). Activation of fibroblast growth factor receptor (FGFR4 and 1) may contribute to the complex pathogenesis of LVH. The aim of this work was to evaluate the therapeutic and prophylactic role of the small molecule inhibitor of FGFR4 (BLU9931) and the small molecule inhibitor of FGFR1 (AZD4547) in alleviating uremic cardiomyopathy. Methods, CKD was induced in rats by 5/6 subtotal nephrectomy operation. fifty Adult male Wistar rats were randomly divided into five groups as follows: (1) Control group, (2) Sham {u2013}operated group, (3) 5/6 subtotal nephrectomy group, (4) 5/6 subtotal nephrectomy + FGFR4 inhibitor: BLU9931 {RF B1}, (5) 5/6 subtotal nephrectomy + FGFR1 inhibitor: AZD4547{] RF B2}. Arterial Blood pressure, electrocardiography ECG and echocardiography ECHO measurement and serum urea and creatinine were recorded in all groups. Results, administration of both the small molecule FGFR4 inhibitor BLU9931 and the small molecule FGFR1 inhibitor AZD4547 2 weeks after the operation resulted in amelioration of cardiac hypertrophy in both RF B1 and RF B2 group at the fifth week. By analysis of echocardiography data, a significant decline in IVSd and LVPWd thicknesses were observed in both RF B1 and RF B2 groups back to the control value. On the other hand, there was no changes in EF% and FS% throughout the study in RF B1 and RF B2. Also, we report significant decrease in the serum urea and serum creatinine in both treated groups. Conclusion, the results of the present study suggested that administration of the small molecule inhibitor of FGFR4: BLU9931 and the small molecule AZD4547 inhibitor of FGFR1 Combined with proper control of renal hypertension can be an early effective prophylactic treatment for preventing adverse uremic cardiovascular complications
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.30.M.Sc.2020.Ne.R (Browse shelf(Opens below)) Not for loan 01010110082564000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.30.M.Sc.2020.Ne.R (Browse shelf(Opens below)) 82564.CD Not for loan 01020110082564000

Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Physiology

Background, left ventricular hypertrophy (LVH) is one of the major cardiovascular complication of Chronic kidney disease (CKD). Activation of fibroblast growth factor receptor (FGFR4 and 1) may contribute to the complex pathogenesis of LVH. The aim of this work was to evaluate the therapeutic and prophylactic role of the small molecule inhibitor of FGFR4 (BLU9931) and the small molecule inhibitor of FGFR1 (AZD4547) in alleviating uremic cardiomyopathy. Methods, CKD was induced in rats by 5/6 subtotal nephrectomy operation. fifty Adult male Wistar rats were randomly divided into five groups as follows: (1) Control group, (2) Sham {u2013}operated group, (3) 5/6 subtotal nephrectomy group, (4) 5/6 subtotal nephrectomy + FGFR4 inhibitor: BLU9931 {RF B1}, (5) 5/6 subtotal nephrectomy + FGFR1 inhibitor: AZD4547{] RF B2}. Arterial Blood pressure, electrocardiography ECG and echocardiography ECHO measurement and serum urea and creatinine were recorded in all groups. Results, administration of both the small molecule FGFR4 inhibitor BLU9931 and the small molecule FGFR1 inhibitor AZD4547 2 weeks after the operation resulted in amelioration of cardiac hypertrophy in both RF B1 and RF B2 group at the fifth week. By analysis of echocardiography data, a significant decline in IVSd and LVPWd thicknesses were observed in both RF B1 and RF B2 groups back to the control value. On the other hand, there was no changes in EF% and FS% throughout the study in RF B1 and RF B2. Also, we report significant decrease in the serum urea and serum creatinine in both treated groups. Conclusion, the results of the present study suggested that administration of the small molecule inhibitor of FGFR4: BLU9931 and the small molecule AZD4547 inhibitor of FGFR1 Combined with proper control of renal hypertension can be an early effective prophylactic treatment for preventing adverse uremic cardiovascular complications

Issued also as CD

There are no comments on this title.

to post a comment.

Click on an image to view it in the image viewer

Local cover image